LON:ROQ Roquefort Therapeutics (ROQ) Share Price, News & Analysis GBX 1.72 -0.13 (-7.03%) As of 10:53 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesBuy This Stock About Roquefort Therapeutics Stock (LON:ROQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roquefort Therapeutics alerts:Sign Up Key Stats Today's Range 1.71▼ 1.8850-Day Range 1.52▼ 2.4052-Week Range 1.40▼ 6.78Volume186,751 shsAverage Volume2.78 million shsMarket Capitalization£2.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRoquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.Read More… Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ROQ Stock News HeadlinesSMALL-CAP WINNERS & LOSERS: Roquefort jumps on Oncogeni dealMarch 10, 2025 | lse.co.ukRoquefort Therapeutics CEO resigns, agrees terms for Oncogeni disposalMarch 10, 2025 | lse.co.ukNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 24, 2025 | Porter & Company (Ad)SMALL CAP IDEA: Roquefort finds pharma diamonds in the roughFebruary 10, 2025 | msn.comRoquefort Therapeutics proposes USD10 million subsidiary saleJanuary 2, 2025 | lse.co.ukGlycoMimetics, Inc. (GKO.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comRoquefort Therapeutics says MK cell therapy patent approved in JapanSeptember 24, 2024 | lse.co.ukTG Therapeutics, Inc. (TGTX)August 10, 2024 | finance.yahoo.comSee More Headlines ROQ Stock Analysis - Frequently Asked Questions How have ROQ shares performed this year? Roquefort Therapeutics' stock was trading at GBX 4.10 at the beginning of the year. Since then, ROQ stock has decreased by 58.0% and is now trading at GBX 1.72. View the best growth stocks for 2025 here. How do I buy shares of Roquefort Therapeutics? Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Roquefort Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ROQ CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,519,059.52 Net Margins-57,057.07% Pretax MarginN/A Return on Equity-29.57% Return on Assets-15.86% Debt Debt-to-Equity Ratio12.37 Current Ratio0.79 Quick Ratio3.07 Sales & Book Value Annual Sales£2,662.35 Price / Sales822.12 Cash FlowGBX 1.15 per share Price / Cash Flow1.49 Book ValueGBX 3.82 per share Price / Book0.45Miscellaneous Outstanding Shares127,254,864Free FloatN/AMarket Cap£2.19 million OptionableNot Optionable Beta0.05 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (LON:ROQ) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.